Argo Biopharma to Present Positive Phase I Results of siRNA Therapeutic BW-20805 for HAE at ACAAI 2025
PR Newswire —
SHANGHAI and BOSTON, Nov. 6, 2025 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced it will present Phase I data for BW-20805 at the American College of Allergy, Asthma & Immunology...